JWJohn T. Williams

John T. Williams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John T. Williams has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Synaptic Vesicle Priming Protein Munc13 Mediates Evoked Somatodendritic Dopamine Release

    by Joseph J. Lebowitz, Aditi Banerjee, Gillian Handy, John T. Williams, Pascal S. Kaeser

    Midbrain dopamine neurons release dopamine not only from their axons but also from their somata and dendrites. Shared and distinct properties have been proposed for somatodendritic and axonal release, but the mechanisms of somatodendritic release remain unclear. We here used gene knock-out, electrophysiology, and imaging to define roles of the synaptic vesicle priming protein Munc13 in somatodendritic dopamine release in comparison with axonal secretion. We characterized mice of either sex and found that Munc13 ablation decreased evoked but not spontaneous somatodendritic dopamine transmission measured as D2 receptor-mediated currents. Imaging with a fluorescent sensor confirmed the importance of Munc13 in evoked somatodendritic and axonal dopamine secretion. Pharmacological experiments revealed a modest contribution of release from norepinephrine axons to D2 receptor-mediated currents, and the relative contribution was enhanced after Munc13 knock-out. Altogether, these data establish important roles of Munc13 in evoked somatodendritic release. These roles are similar to Munc13 functions in axonal dopamine release and at fast synapses. Spontaneous midbrain dopamine release was not impaired by Munc13 ablation from dopamine neurons and may rely on a release pathway that is independent of the prototypical release machinery employed at synapses.

  • Grin2a knockout in adolescent dopamine neurons disrupts prediction error signaling and produces a phenotype relevant to schizophrenia

    by Michelle L. Kielhold, David S. Jacobs, Alejandro Torrado Pacheco, Merridee J. Lefner, Alina P. Bogachuk, Joseph J. Lebowitz, Angela J. Langdon, John T. Williams, Larry S. Zweifel, Bita Moghaddam

    Adolescence is associated with the emergence of several psychiatric disorders including schizophrenia. Recent studies have identified both common and rare variants of the GRIN2A gene as risk factors for schizophrenia. GRIN2A encodes the GluN2A subunit of the NMDA receptor and is developmentally regulated with low cortical expression at birth that reaches adult levels in adolescence. While global knockouts of Grin2a produce abnormal behavior in mice, little is known about the functional consequences of manipulating this gene specifically in dopamine neurons, a cell type implicated in schizophrenia pathophysiology. We find that, unlike cortical regions where GluN2A levels remain stable throughout adolescence, GluN2A naturally declines in dopamine neuron-containing brain regions in this developmental period. This suggests that adolescent dopamine neurons may be especially vulnerable to further reductions of GluN2A caused by damaging GRIN2A variants. Consistent with this idea, we find that a genetically driven reduction of Grin2a in midbrain dopamine neurons of adolescent rats is sufficient to recapitulate behaviors that are consistent with some aspects of positive symptoms of schizophrenia. These include hypersensitivity to amphetamine, diminished effort optimization, impaired ability to use feedback to modify motivated actions, and disrupted dopamine release during prediction error signaling. Computational modeling of the behavioral data further revealed reduced capacity to gate associative processes based on previous learning. These data describe a novel role for GluN2A-containing dopamine neurons in prediction error signaling and provide a rodent model to explore how mutations in GRIN2A may contribute to the latent presentation of dopamine-related symptoms in schizophrenia.


  • Open Access

    The synaptic vesicle priming protein Munc13 mediates evoked somatodendritic dopamine release

    by Joseph J Lebowitz, Aditi Banerjee, Gillian Handy, John T Williams, Pascal S Kaeser

    Midbrain dopamine neurons secrete dopamine from their somata and dendrites in addition to their axonal release. Shared and distinct properties have been proposed for somatodendritic and axonal release, but the mechanisms of somatodendritic release remain unclear. We here used mouse genetics, electrophysiology, and imaging to define roles of the synaptic vesicle priming protein Munc13 in somatodendritic release in comparison to axonal secretion. Munc13 ablation in dopamine neurons decreased evoked but not spontaneous somatodendritic dopamine transmission measured as D2 receptor-mediated currents. Imaging with a fluorescent dopamine sensor confirmed this finding and established comparable importance for Munc13 in somatodendritic and axonal secretion. Pharmacological experiments revealed that release from adrenergic terminals contributes to D2 receptor-mediated currents, and their relative contribution was enhanced after Munc13 knockout. Altogether, these data establish important roles for Munc13 in evoked somatodendritic release. These roles are similar to Munc13 functions in axonal dopamine release and at fast synapses. Spontaneous midbrain dopamine release does not necessitate Munc13 in dopamine neurons and may rely on a release pathway that is independent of the prototypical release machinery employed at synapses.


  • Mice carrying the human dopamine D2 receptor pathogenic mutation p.Met374Arg exhibit hyperactivity and aberrant D2 receptor function

    by Dayana Rodriguez-Contreras, Joseph J. Lebowitz, Cheryl Reed, Elizabeth Walker-Ziegler, David C. Buck, Guochuan Li, Shu Xie, Yulong Li, Lev M. Fedorov, Tamara J. Phillips, et al.


  • Open Access

    Tolerance in Thalamic Paraventricular Nucleus Neurons Following Chronic Treatment of Animals with Morphine

    by Omar Koita, Joseph J. Lebowitz, John T. Williams

    Neurons in the paraventricular nucleus of the thalamus (PVT) integrate visceral and limbic inputs and project to multiple brain regions to bias behavior toward aversive or defensive states. This study examines MOR signaling in anterior PVT neurons in brain slices from untreated and morphine-treated animals. Imaging in a MOR-Cre reporter rat revealed extensive expression in aPVT cells, and the application of [Met]5−enkephalin (ME) induced outward currents which were abolished by the MOR-selective antagonist CTAP. A saturating concentration of ME resulted in desensitization that was blocked by compound 101, indicating a phosphorylation-dependent process. The opioid sensitivity of amygdala-, nucleus accumbens-, and prefrontal cortex-projecting neurons was then examined. Neurons that projected to the amygdala were more sensitive to ME than cortical- and accumbal-projecting cells. Following chronic treatment, tolerance to morphine was found in neurons projecting to the amygdala and nucleus accumbens with a trend toward tolerance observed in neurons projecting to the prefrontal cortex. The results reveal that adaptations to chronic opioid exposure are in the aPVT circuits contribute to affective pain processing and may provide specific insights into the etiology of withdrawal following the cessation of opioid use.


  • Open Access

    Synaptotagmin-7 Counteracts Short-Term Depression during Phasic Dopamine Release

    by Joseph J. Lebowitz, Sarah A. Kissiwaa, Kim A. Engeln, Anna M. Bowman, John T. Williams, Skyler L. Jackman

    Dopamine neurons switch from tonic pacemaker activity to high-frequency bursts in response to salient stimuli. These bursts lead to superlinear increases in dopamine release, and the degree of this increase is highly dependent on firing frequency. The superlinearity and frequency dependence of dopamine release implicate short-term plasticity processes. The presynaptic Ca2+-sensor synaptotagmin-7 (SYT7) has suitable properties to mediate such short-term plasticity and has been implicated in regulating dopamine release from somatodendritic compartments. Here, we use a genetically encoded dopamine sensor and whole-cell electrophysiology inSyt7KO mice to determine how SYT7 contributes to both axonal and somatodendritic dopamine release. We find that SYT7 mediates a hidden component of facilitation of release from dopamine terminals that can be unmasked by lowering initial release probability or by predepressing synapses with low-frequency stimulation. Depletion of SYT7 increased short-term depression and reduced release during stimulations that mimic in vivo firing. Recordings of D2-mediated inhibitory postsynaptic currents in the substantia nigra pars compacta (SNc) confirmed a similar role for SYT7 in somatodendritic release. Our results indicate that SYT7 drives short-term facilitation of dopamine release, which may explain the frequency dependence of dopamine signaling seen in vivo.


  • Open Access

    Synaptotagmin-1 is a Ca2+ sensor for somatodendritic dopamine release

    by Joseph J. Lebowitz, Aditi Banerjee, Claire Qiao, James R. Bunzow, John T. Williams, Pascal S. Kaeser


  • Co‐activation of GPCRs facilitate GIRK‐dependent current

    by Alec F. Condon, Naeem Asad, Timothy M. Dore, John T. Williams

    The activity of dopamine neurons is dependent on both intrinsic properties and afferent projections. One potent form of inhibition is mediated by the activation of two inhibitory G protein‐coupled receptors, D2 and GABAB receptors. Each of these receptors activates G protein‐coupled inwardly rectifying potassium (GIRK) channels. Recordings in brain slices have shown that co‐activation using saturating concentrations of agonists results in occlusion of the GIRK current. The present study examined the interaction between D2 and GABAB receptors using transient applications of sub‐saturating concentrations of agonists where the co‐application of one agonist resulted in both facilitation and inhibition (desensitization) of the other. The heterologous facilitation was modelled based on the known cooperative interaction between the G protein βγ subunits and GIRK channels. The results indicate that a low tonic level of G βγ results in facilitation of GIRK current and a high level of G βγ results in occlusion. The kinetics of the current induced by transient receptor activation is prolonged in each case. The results suggest that the cooperative interaction between G βγ subunits and GIRK channels determines both the amplitude and kinetics of GPCR‐dependent current. image Key points: Inhibitory D2 and GABAB receptors modulate dopamine neuron activity through shared G protein‐coupled inwardly rectifying potassium (GIRK) channels. This study reports robust bidirectional interactions between these two converging receptor pathways. Coincident activation of D2 and GABAB receptors leads to facilitation of GIRK channel currents, augmenting both amplitude and prolonging the duration of phasic responses. Activation of either D2 or GABAB receptors also acutely desensitized the GIRK channel current induced by D2 receptor activation that rapidly recovers following termination of desensitizing stimulus. Results demonstrate that the activity of either G protein‐coupled receptor system must be considered in the context of other G protein‐coupled receptors.


  • Open Access

    Cellular Tolerance Induced by Chronic Opioids in the Central Nervous System

    by Sweta Adhikary, John T. Williams

    Opioids are powerful analgesics that elicit acute antinociceptive effects through their action the mu opioid receptor (MOR). However opioids are ineffective for chronic pain management, in part because continuous activation of MORs induces adaptive changes at the receptor level and downstream signaling molecules. These adaptations include a decrease in receptor-effector coupling and changes to second messenger systems that can counteract the persistent activation of MORs by opioid agonists. Homeostatic regulation of MORs and downstream signaling cascades are viewed as precursors to developing tolerance. However, despite numerous studies identifying crucial mechanisms that contribute to opioid tolerance, no single regulatory mechanism that governs tolerance in at the cellular and systems level has been identified. Opioid tolerance is a multifaceted process that involves both individual neurons that contain MORs and neuronal circuits that undergo adaptations following continuous MOR activation. The most proximal event is the agonist/receptor interaction leading to acute cellular actions. This review discusses our understanding of mechanisms that mediate cellular tolerance after chronic opioid treatment that, in part, is mediated by agonist/receptor interaction acutely.


  • Open Access

    Gait Abnormalities and Aberrant D2 Receptor Expression and Signaling in a Mouse Model of the Human Pathogenic Mutation DRD2 I212F

    by Dayana Rodriguez-Contreras, Sheng Gong, Joseph J Lebowitz, Lev M Fedorov, Naeem Asad, Timothy M Dore, Christopher P Ford, John T Williams, Kim A Neve

    A dopamine D2 receptor mutation was recently identified in a family with a novel hyperkinetic movement disorder (Mov Disord 36 : 729-739, 2021). That allelic variant D2-I 212 F is a constitutively active and G protein-biased receptor. We now describe mice engineered to carry the D2-I 212 F variant, Drd2 I212F . The mice exhibited gait abnormalities resembling those in other mouse models of chorea and/or dystonia, and had decreased striatal D2 receptor expression. Electrically evoked IPSCs in midbrain dopamine neurons and striatum from Drd2 I212F mice exhibited slow onset and decay compared to wild type mice. In the presence of dopamine, current decay initiated by photolytic release of sulpiride from CyHQ-sulpiride was slower in midbrain slices from Drd2 I212F mice than Drd2 +/+ mice. Furthermore, in contrast to wild type mice in which dopamine is more potent at neurons in the nucleus accumbens than in the dorsal striatum, reflecting activation of Gα o vs. Gα i1 , dopamine had similar potencies in those two brain regions of Drd2 I212F mice. Repeated cocaine treatment, which decreases dopamine potency in the nucleus accumbens of wild type mice, had no effect on dopamine potency in Drd2 I212F mice. The results demonstrate the utility of this mouse model for investigating the role of pathogenic DRD2 variants in early-onset hyperkinetic movement disorders.